EOCN.US Eocene Ltd.

Healthcare Biotechnology USA Stocks
2.48 USD
Close of Nov 14, 2026
2.05 12.32
Market cap
USD 2.65M
P/E
-
P/B
0.21x
ROE
-72.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is EOCN.US undervalued?

Graham number

The Graham number of Eocene Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eocene Ltd. fundamental analysis

No fundamental analysis for Eocene Ltd. yet.

Eocene Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eocene Ltd.

Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE…

Full company profile